MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2018 International Congress

    Effects of a combined approach with botulinum toxin (BONT) and motor-learning techniques (MLT) on sensori-motor functional connectivity in patients with cervical dystonia (CD)

    A. Castagna, M. Cabinio, M. Ramella, L. Magistrelli, M. Laganà, F. Baglio (Milano, Italy)

    Objective: Aim of this study is to evaluate sensori-motor connectivity associated with a multimodal BoNT/MLT teratment in CD patients using advanced Resonance Imaging (MRI) techniques.…
  • 2018 International Congress

    Prevalence and Correlates of Anxiety & Depression in Cervical Dystonia

    M. Al Hussona, I. Ndukwe, S. O'Riordan, R. Beck, R. Reilly, M. Hutchinson (Dublin, Ireland)

    Objective: Our aim was to assess the prevalence and severity of mood disorder in our Cervical Dystonia population attending the botulinum toxin clinic and to…
  • 2018 International Congress

    Generation and in-depth characterization of induced pluripotent stem cell (iPSC) lines from 10 affected and unaffected carriers of THAP1 mutations

    H. Baumann, M. Trilck, M. Jahn, A. Münchau, V. Kostic, C. Klein, P. Seibler, K. Lohmann (Luebeck, Germany)

    Objective: To establish induced pluripotent stem cells (iPSCs) of affected and unaffected Mutation carriers to investigate disease mechanisms of THAP1 in dystonia. Background: Mutations in…
  • 2018 International Congress

    A Registry of Real-World Outcomes Using Deep Brain Stimulation for the Treatment of Dystonia

    J. Krauss, C. Nicholson, M. Barbe, V. Visser-Vanderwalle, A. Kuehn, M. Poetter-Nerger, R. Jain, H. Scholtes, N. Van Dyck, A. Albanese (Hannover, Germany)

    Objective: The objective of this device registry entails collecting clinical outcomes, economic value and technical performance of a Deep Brain Stimulation (DBS) system capable of…
  • 2018 International Congress

    Frequency and Phenoptypic Spectrum of KMT2B Mutations in Childhood-Onset Dystonia: Results from a Single-Centre Cohort Study

    M. Carecchio, G. Zorzi, F. Invernizzi, C. Panteghini, L. Romito, F. Zibordi, V. Leuzzi, S. Galosi, P. Morana, B. Morana, C. Piano, A. Bentivoglio, C. Reale, F. Girotti, M. Topf, A. Joseph, M. Kurian, S. Lubbe, B. Garavaglia, N. Mencacci, N. Nardocci (Milan, Italy)

    Objective: To assess the frequency of KMT2B mutations in a cohort of patients with childhood-onset dystonia and characterize the related molecular and phenotypic spectrum. Background:…
  • 2018 International Congress

    Prevalence of REM Sleep Behavior Disorder in Sun City, Arizona

    D. Shprecher, A. Intorcia, M. Glass, J. Curry, J. Walker, B. Cutler, M. Callan, G. Serrano, N. Zhang, L. Sue, K. Davis, T. Beach (Sun City, AZ, USA)

    Objective: Determine prevalence of REM Sleep Behavior Disorder (RBD) in Sun City, Arizona Background: RBD is the strongest known clinical risk factor for neurodegenerative disorders…
  • 2018 International Congress

    Prevalence and characteristics of patients with progressive supranuclear palsy (PSP) in US health insurance claims data

    E. Viscidi, T. Dam, M. Juneja, L. Li, H. Krzywy, S. Eaton, S. Chen, S. Hall, A. Dilley (Cambridge, MA, USA)

    Objective: To estimate the prevalence of PSP in the United States (US) and present a profile of PSP patients. Background: Progressive supranuclear palsy (PSP) is…
  • 2018 International Congress

    Decision making in Huntington’s disease

    B. Heim, M. Peball, P. Ellmerer, C. Saft, S.M. von Hein, W. Poewe, K. Seppi, A. Djamshidian (Innsbruck, Austria)

    Objective: To investigate perceptual decision making and reflexion impulsivity in preclinical and manifest patients with Huntington’s disease (HD). Background: Huntington’s disease (HD) is an autosomal…
  • 2018 International Congress

    Driving performance of Huntington’s disease gene carriers

    M. Jacobs, E. Hart, Y. Mejia Miranda, G.J. Groeneveld, J. van Gerven, R. Roos (Leiden, Netherlands)

    Objective: To investigate if differences in driving performance between Huntington's disease (HD) gene carriers and healthy individuals can be detected with a driving simulator. Furthermore,…
  • 2018 International Congress

    Botulinum toxin A (BoNT A) treatment of postsurgical/posttraumatic focal movements not responding to oral therapy

    A. Lozza, A. Castagna, G. Castelnovo, E. Alfonsi, A. Montini, L. Marchetta, M. Fresia, A. Arrigo, R. Manni (Pavia, Italy)

    Objective: We report three cases of focal movement disorder following trauma or surgery. Oral therapies were ineffective in both patients and symptoms dramatically improved after…
  • « Previous Page
  • 1
  • …
  • 145
  • 146
  • 147
  • 148
  • 149
  • …
  • 177
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • To be or not to bupropion: a drug-induced parkinsonism?
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
      • Help & Support
      • About Us
      • Cookies & Privacy
      • Wiley Job Network
      • Terms & Conditions
      • Advertisers & Agents
      Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
      Wiley